• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Insufficient evidence for using muscle relaxants to effectively relieve lower back pain

byDavy LauandAlex Chan
August 5, 2021
in Chronic Disease, Orthopedic Surgery, Surgery
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Very low certainty evidence exists suggesting that non-benzodiazepine antispasmodics for lower back pain can reduce pain intensity, but not reduce disability, within two weeks.

2. More placebo controlled trials with different drug classes and durations of follow-up are needed to determine the efficacy, acceptability, and safety of muscle relaxants for lower back pain.

Evidence Rating Level: 1 (Excellent)

Lower back pain not only contributes significantly to the burden of disability around the world, but it is also associated with a very high economic burden, costing the United States approximately 134.5 billion dollars in healthcare expenses for 2016. Although muscle relaxants are the 3rd most commonly prescribed drug for lower back pain, guidelines in different countries conflict with each other, such as the US recommending non-benzodiazepine antispasmodics specifically, Belgium recommending no muscle relaxants, and the UK not making a recommendation either way. A previous systematic review showed that muscle relaxants provided a clinically significant decrease in pain (mean of 21.3 points on a 100-point scale). However, this review did not encompass randomized controlled trials (RCTs) from clinical trial registries. Therefore, the current review examined RCTs across numerous search databases and clinical trial registries to determine muscle relaxants’ efficacy, acceptability, and safety.

Overall, the study found very low certainty evidence that non-benzodiazepine antispasmodics diminished pain intensity at 2 weeks follow-up, as well as low certainty evidence that there may be a greater risk of adverse events. However, no difference in reduction of disability or acceptability of the drug regimen was found. This review underlies the need for higher quality RCTs assessing many classes of muscle relaxants and follow-up durations, as the body of research was limited for conditions other than non-benzodiazepine antispasmodics with 2 weeks follow-up.

Click here to read the study in BMJ

Relevant Reading: Efficacy and tolerability of muscle relaxants for low back pain: Systematic review and meta-analysis

RELATED REPORTS

Medical cannabis provides little improvement to sleep in chronic pain patients

Wellness Check: Sleep

Changes in opioid or nonopioid pain treatments not attributable to state opioid prescribing laws

In-Depth [systematic review and meta-analysis]: This review included RCTs where the study population consisted of adults with non-specific lower back pain. Participants were randomized to a group receiving a dose of muscle relaxant or a group receiving usual care, a placebo, or no treatment. In some RCTs, comparison were made between patients receiving two different muscle relaxants versus just one. The outcomes assessed were reduction in pain intensity and disability scores (on 100-point scales), acceptability (number of participants withdrawing from treatment for any reason), adverse events, and tolerability (number of participants withdrawing due to adverse events). The determination of whether evidence was low or high certainty was made using the GRADE approach. Overall, 49 studies were included in the review, and 31 in the meta-analysis. The results showed with very low certainty that non-benzodiazepine antispasmodics were associated with diminished pain intensity scores on or before 2 weeks (mean difference -7.7, 95% CI -12.1 to -3.3). There was also very low certainty for a reduction in disability scores (-3.3, 95% CI -7.3 to 0.7). Between 3 and 13 weeks, there was moderate certainty that no reduction in pain was found (mean difference 0.6, 95% CI -4.5 to 5.7). As well, there was very low certainty for finding no difference in acceptability (relative risk 0.8, 95% CI 0.6-1.1). There was also low certainty evidence for increased risk in adverse events (RR 1.6, 95% CI 1.2-2.0). With regards to drug classes other than non-benzodiazepine antispasmodics, no differences in efficacy were found except for a reduction in disability for benzodiazepines between 3 and 13 weeks (mean difference -6.9, 95% CI -12.1 to -1.7, moderate certainty evidence), although this data came from only one RCT. In general, many of the findings were of low certainty, whether the results were statistically significant or insignificant, demonstrating the need for larger, placebo-controlled RCTs to help determine the efficacy of muscle relaxants for lower back pain.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: back painchronic pain
Previous Post

Prevalence of toxigenic and non-toxigenic asymptomatic Clostridioides difficile colonization in pediatric populations

Next Post

Complete revascularization guided by fractional flow reserve not superior to angiography

RelatedReports

Parental cannabis use increasing, cigarette use decreasing
Chronic Disease

Medical cannabis provides little improvement to sleep in chronic pain patients

May 27, 2022
Sleep duration, sleepiness, chronotype have variable associations with teen self-regulation
Wellness

Wellness Check: Sleep

May 26, 2022
Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use
Chronic Disease

Changes in opioid or nonopioid pain treatments not attributable to state opioid prescribing laws

March 30, 2022
#VisualAbstract: Therapeutic aquatic exercise is superior at improving disability and severity of low back pain compared to physical therapy
StudyGraphics

#VisualAbstract: Therapeutic aquatic exercise is superior at improving disability and severity of low back pain compared to physical therapy

January 19, 2022
Next Post
Drug-coated balloons are noninferior to drug-eluting stents for treatment of small vessel coronary artery disease

Complete revascularization guided by fractional flow reserve not superior to angiography

Shared decision-making tool for antidepressants improves patient and physician satisfaction

Wellness Check: Mental Health

#VisualAbstract Sporotrichosis-associated cutaneous hypersensitivity reactions occur more frequently in the fixed cutaneous form

#VisualAbstract Sporotrichosis-associated cutaneous hypersensitivity reactions occur more frequently in the fixed cutaneous form

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.